Stocks Health care STOK
NASDAQ · Health careStoke Therapeutics, Inc. (STOK)
Stoke Therapeutics, Inc. brought in $28.2M of revenue over the twelve months to September 30, 2026, down 86.3% from a year earlier. It posted a net loss of $243.2M. Operating cash flow minus capital spending left $44.9M of free cash flow in fiscal 2025. At September 30, 2026 it held $107.3M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 3, 2026.
Key facts about Stoke Therapeutics, Inc.
- Net worth
- Stoke Therapeutics, Inc. has a market value (market cap) of $1.8B at the latest share price, and shareholders' equity of $352.6M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $184.4M (+404.5% year on year), with a net loss of $6.9M. Over the 12 months to September 30, 2026: revenue $28.2M, net loss $243.2M.
- Cash flow
- In fiscal 2025 operations brought in $45.6M of cash; after $670K of capital spending, free cash flow was $44.9M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 3, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Stoke Therapeutics, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Stoke Therapeutics, Inc. does
Stoke Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker STOK.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $184.4M | -$6.9M | -$0.12 | $44.9M |
| 2024 | $36.6M | -$89M | -$1.65 | -$87.1M |
| 2023 | $8.8M | -$104.7M | -$2.38 | -$82.7M |
| 2022 | $12.4M | -$101.1M | -$2.60 | -$35.8M |
| 2021 | n/a | -$85.8M | -$2.34 | -$68.1M |
| 2020 | n/a | -$52.2M | -$1.56 | -$43.3M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where STOK ranks in Health care
Latest SEC filings
What Stoke Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026Passive stake changed SCHEDULE 13G/A
- November 3, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 5.9% to $11.3M versus the same quarter last year; diluted EPS -$1.08 versus -$0.65.
- October 29, 2026
- September 30, 2026Passive stake (5% or more) SCHEDULE 13G
- September 25, 2026Executive or director change8-KStoke Therapeutics announced the resignation of director Edward M. Kaye and the appointment of Alexander (Bo) Cumbo to its Board of Directors.
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 12, 2026Passive stake changed SCHEDULE 13G/A
- August 6, 2026Passive stake changed SCHEDULE 13G/A
- August 3, 2026Other event 8-K
- August 3, 2026
What is STOK worth? A DCF from its reported cash flow
Insider trades
What the people running Stoke Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $1.1M worth of shares in the last 90 days and bought none on the open market. 38% of the selling was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| November 2, 2026 | Ticho BarryCHIEF MEDICAL OFFICER | Soldpre-planned (10b5-1) | 6,995 | $184.5K |
| November 2, 2026 | Ticho BarryCHIEF MEDICAL OFFICER | Soldpre-planned (10b5-1) | 200 | $5.4K |
| October 2, 2026 | Allan JonathanGENERAL COUNSEL & CORP SEC | Soldpre-planned (10b5-1) | 627 | $16.5K |
| October 1, 2026 | Ticho BarryCHIEF MEDICAL OFFICER | Soldpre-planned (10b5-1) | 1,051 | $27.5K |
| September 1, 2026 | Ticho BarryCHIEF MEDICAL OFFICER | Soldpre-planned (10b5-1) | 3,945 | $120.4K |
| September 1, 2026 | Ticho BarryCHIEF MEDICAL OFFICER | Soldpre-planned (10b5-1) | 1,600 | $49.7K |
| August 18, 2026 | Kaye Edward M. MDDirector | Sold | 11,930 | $381.8K |
| August 18, 2026 | Kaye Edward M. MDDirector | Sold | 637 | $20.7K |
Who owns STOK
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Skorpios Trust13D, may seek influence | 16.9% | September 23, 2024 |
| RTW Investments, LP13G, passive with 1 related filers | 9.9% | May 15, 2026 |
| Fmr LLC13G, passive with 1 related filers | 8.5% | August 6, 2026 |
| Redmile Group, LLC13G, passive with 2 related filers | 6.7% | May 15, 2026 |
| Lynx1 Capital Management LP13G, passive with 1 related filers | 6.5% | August 14, 2026 |
| Morgan Stanley13G, passive with 1 related filers | 6.5% | February 3, 2025 |
| Baker Bros. Advisors LP13G, passive with 3 related filers | 5.8% | February 17, 2026 |
| Bvf Partners L P13G, passive with 9 related filers | 5.6% | September 30, 2026 |
| Wellington Management Group LLP13G, passive with 3 related filers | 5.2% | May 15, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 198 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 5,877,357 | +491,643 |
| Rtw Investments, LP | 5,623,525 | 0 |
| Fmr LLC | 5,313,100 | -70,566 |
| Lynx1 Capital Management LP | 4,038,404 | -725,269 |
| Redmile Group, LLC | 3,945,920 | -218,200 |
| Wellington Management Group Llp | 3,519,301 | +423,601 |
| Morgan Stanley | 3,452,795 | +29,515 |
| Baker Bros. Advisors LP | 3,336,697 | 0 |
| Toronto Dominion Bank | 3,173,258 | 0 |
| State Street Corp | 2,852,240 | +575,728 |
| Vanguard Capital Management LLC | 2,586,937 | +231,334 |
| Bvf Inc | 2,547,557 | 0 |
| Assenagon Asset Management S.A. | 2,256,776 | +1,349,761 |
| Siren, L.L.C. | 1,995,347 | 0 |
| Deerfield Management Company, L.P. | 1,823,500 | 0 |
| Jupiter Topco LLC | 1,814,408 | new |
| Geode Capital Management, LLC | 1,524,309 | +202,049 |
| Dimensional Fund Advisors LP | 1,013,911 | +23,975 |
| Polar Capital Holdings Plc | 833,716 | -298,795 |
| EcoR1 Capital, LLC | 735,000 | +635,000 |
Insiders
8 insiders reported holding 496,345 shares in total, about $13.8M at the last price.
| Holder | Shares |
|---|---|
| Krainer Adrian R.Director | 283,302 |
| Kaye Edward M. MDDirector | 124,557 |
| Tzianabos ArthurInterim Executive Chair, Director | 31,339 |
| Allan JonathanGENERAL COUNSEL & CORP SEC | 20,598 |
| Ticho BarryCHIEF MEDICAL OFFICER | 11,864 |
| Hoitt JasonChief Patient Officer | 10,276 |
| Leggett ThomasChief Financial Officer | 10,172 |
| Levin Arthur ADirector | 4,237 |
Questions about STOK
What does Stoke Therapeutics, Inc. do?
Stoke Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as STOK. Its shares trade on NASDAQ under the ticker STOK.
What is Stoke Therapeutics, Inc.'s net worth?
Stoke Therapeutics, Inc. has a market value (market cap) of $1.8B at the latest share price, and shareholders' equity of $352.6M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Stoke Therapeutics, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $243.2M on revenue of $28.2M.
How much revenue does Stoke Therapeutics, Inc. make?
Over the twelve months to September 30, 2026 Stoke Therapeutics, Inc. reported revenue of $28.2M. That is 86.3% less than a year earlier.
When did Stoke Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 3, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the passive stake changed from November 5, 2026.
When is Stoke Therapeutics, Inc.'s next earnings report?
Stoke Therapeutics, Inc.'s next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare STOK with
Follow STOK
Get an email when Stoke Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Stoke Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.